Table 2.

Clinical Trials Assessing Cirrhotic Liver Disease.

Study	Author year	Sample size	Methodology	Stem cell	Author conclusions
1	Gaia et al,23 2006	Active Treatment: 8 (5 male) Healthy donors: 40	Mobilization using G-CSF	HSC	Safe and feasible. Increase in cell count with potential regeneration
2	Khan et al,29 2010	Active Treatment: 4	Infusion of human fetal stem cells	hHPC	Significance decrease in patient MELD score. may be used as supportive treatment
3	Terai et al,24 2006	Active Treatment: 9 (8 male)	Infusion of BM taken from ileum	MNC	Improvement of liver function
4	Kharaziha et al,28 2009	Active Treatment: 8 (4 male)	Infusion of BM taken from iliac spine	MSC	No increase in morbidity or mortality. May improve liver function
5	Mohamadnejad et al,25 2007	Active Treatment: 4 (1 male)	Infusion of BM taken from iliac crest	MSC	Safe and feasible. Some improvement in liver function
6	Mohamadnejad et al,26 2007	Active Treatment: 4 (2 male)	Infusion of BM taken from iliac crest	HSC	Infusion not safe through hepatic artery due to side effects
7	Nikeghbalian et al,31 2011	HSC Treatment: 3 (1 male) MNC Treatment: 3 (2 male)	Infusion of BM taken from iliac crest	HSC MNC	Safe and feasible. No significant difference between HSC and MNC
8	Lin et al,32 2012	Active Treatment: 38 Placebo Treatment: 16	Infusion of cells derived from umbilical cord	MSC	Safe and has potential to improve quality of life of patient
9	Zhang et al,3 2012	Active Treatment: 30 Placebo Treatment: 15	Infusion of cells derived from umbilical cord	MSC	Safe and feasible. Can improve liver function
10	Salama et al,30 2010	Active Treatment: 90 (78 male) Placebo Treatment: 50 (38 male)	Mobilization using G-CSF followed by infusion from iliac crest	HSC	Safe and tolerated. HSC transplantation can be used as supportive treatment.
11	Pai et al,27 2008	Active Treatment: 9 (6 male)	Mobilization using G-CSF followed by infusion	HSC	Safe and feasible. Improvement in liver function